Why Revvity’s Signals Xynthetica integration with Lilly TuneLab could reshape biotech AI
Revvity and Lilly team up to scale AI-powered drug discovery. Find out how federated learning could reshape access to predictive models across biotech.
Eli Lilly taps Chai Discovery to accelerate biologics with AI-generated candidates
Eli Lilly partners with Chai Discovery to deploy AI for antibody drug design. Find out what this means for the future of biologics R&D.
Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
From Parkinson’s to platform scalability: What’s next for Sinopia’s LEADS technology
Sinopia Biosciences receives NIH grant to expand its LEADS platform. Find out how AI and metabolomics could transform drug discovery.
Can AI and chemistry finally converge to drug transcription factors? The race to target the cell’s command center
For decades, pharmaceutical pipelines have danced around one of biology’s most powerful but untouchable entities: transcription factors. These master regulators control gene expression and orchestrate cellular behavior, yet their structure and function have kept them out of reach for small molecule therapeutics. Unlike enzymes or receptors, transcription factors operate deep within the cell nucleus, often […]
Can PRISM BioLab and Talus Bio finally drug the undruggable with AI and PPI chemistry?
PRISM BioLab and Talus Bio aim to drug the undruggable with AI–PPI chemistry. Find out how this platform could transform transcription factor drug discovery.
How the Brii–OpenBench deal could redefine early-stage drug discovery economics
Brii Biosciences Limited and OpenBench, Inc. have announced a strategic collaboration to integrate OpenBench’s structure-based artificial intelligence platform into Brii Biosciences’ discovery efforts. The partnership grants Brii Biosciences exclusive rights to novel lead compounds identified through OpenBench’s proprietary screening technology. The agreement includes an option to expand into additional programs, underscoring Brii Biosciences’ push into […]
Inside Insilico Medicine’s CKD push: AI-driven ISM4808 heads to Greater China with TaiGen
Insilico Medicine has licensed its AI-discovered oral PHD inhibitor ISM4808 to TaiGen Biotechnology for exclusive development and commercialization in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan. The deal follows Investigational New Drug clearance in China in 2023 and positions TaiGen to bring the asset into clinical trials targeting anemia associated […]